John M. Leonard plans $293K Intellia stock sale

Intellia Therapeutics, Inc. (symbol NTLA) received a notice that John M. Leonard intends to sell common stock under Rule 144.

Rhea-AI Filing Summary

Intellia Therapeutics, Inc. (symbol NTLA) received a notice that John M. Leonard intends to sell common stock under Rule 144. The planned sale covers 22,675 shares of common stock through UBS Financial Services Inc., with an aggregate market value of $293,641.25, listed on NASDAQ and noted with a proposed sale date of 08/20/2026.

The shares relate to earlier acquisitions from stock option exercises by the issuer, including 3,000 shares on 04/13/2021 and 19,675 shares on 02/09/2021, both for cash. UBS Financial Services Inc. signed as attorney-in-fact for John Leonard.

Key Figures

Shares to be sold: 22,675 shares of common stock Aggregate market value: $293,641.25 Proposed sale date: 08/20/2026 +2 more

5 metrics

Shares to be sold 22,675 shares of common stock Planned Rule 144 sale for John M. Leonard

Aggregate market value $293,641.25 Value of 22,675 NTLA shares proposed for sale

Proposed sale date 08/20/2026 Date associated with the planned Rule 144 sale

Shares from 04/13/2021 option exercise 3,000 shares Common stock acquired via stock option exercise for cash

Shares from 02/09/2021 option exercise 19,675 shares Common stock acquired via stock option exercise for cash

Key Terms

Rule 144, stock option exercise, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

stock option exercise financial

"Common | 04/13/2021 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

attorney-in-fact regulatory

"as attorney-in-fact for John Leonard"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for NTLA disclose?

It discloses that John M. Leonard intends to sell 22,675 shares of Intellia Therapeutics, Inc. common stock under Rule 144, through UBS Financial Services Inc., with an aggregate market value of $293,641.25 and a noted proposed sale date of 08/20/2026.

How many NTLA shares are planned to be sold under this Form 144?

The notice states that 22,675 shares of Intellia Therapeutics, Inc. common stock are planned to be sold. The filing lists these shares with an aggregate market value of $293,641.25 and identifies UBS Financial Services Inc. as the broker for the transaction.

What is the approximate market value of the NTLA shares in this Form 144?

The filing reports an aggregate market value of $293,641.25 for the 22,675 shares of Intellia Therapeutics, Inc. common stock proposed to be sold under Rule 144, with the sale to be executed through UBS Financial Services Inc.

When are the NTLA shares in this Form 144 expected to be sold?

The notice indicates a proposed sale date of 08/20/2026 for the 22,675 shares of Intellia Therapeutics, Inc. common stock to be sold under Rule 144 through UBS Financial Services Inc.

How were the NTLA shares in the Form 144 originally acquired?

The filing shows the shares were acquired via stock option exercises from the issuer: 3,000 shares on 04/13/2021 and 19,675 shares on 02/09/2021, both for cash consideration.

Who is executing the planned sale of NTLA shares in the Form 144?

The broker identified is UBS Financial Services Inc., and the Form 144 is signed “/s/ UBS Financial Services Inc, as attorney-in-fact for John Leonard,” indicating UBS is acting under a power of attorney.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/20/2026 - 04:04 PM Accepted by SEC EDGAR 08/20/2026 - 04:03 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001563584
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Intellia Therapeutics, Inc.
SEC File Number	001-37766
Address of Issuer	40 ERIE STREET SUITE 130 CAMBRIDGE MASSACHUSETTS 02139
Phone	857-285-6200
Name of Person for Whose Account the Securities are To Be Sold	LEONARD JOHN M
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	22675	293641.25	140126693	08/20/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	04/13/2021	Stock Option Exercise	Issuer			3000	04/13/2021	Cash
Common	02/09/2021	Stock Option Exercise	Issuer			19675	02/09/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/20/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/21/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for John Leonard
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)